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Abstract
NK cells are important in regulating hepatic fibrosis via their cytotoxic killing of hepatic stellate
cells (HSCs). NK cells are activated by both cytokines such as IL-12 and IL-18, and innate immune
stimuli such as ligation of TLRs. The secretion of IL-18 depends upon activation of the inflamma-
some, whereas TLRs are stimulated by microbial products. In the case of NK cells, IL-18 acts syn-
ergistically with stimulation of TLR3 to cause cell activation and cytotoxic function. In the present
study, we activated NK cells to kill HSCs via IL-18 and TLR3 ligand stimulation, and dissected the
signaling pathways or molecules critical for such activation or killing. We find that such activa-
tion depends on signaling via the p38/PI3K/AKT pathway, and that the activatedNK cells mediate
HSC death in a TRAIL-involved mechanism. As liver fibrosis is a major global health problem with
no good solution, these results emphasize that the p38/PI3K/AKT pathway in NK cells may be a
novel drug target to promote fibrosis regression.
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1 INTRODUCTION
Liver fibrosis,which result fromchronic liver injury of any etiology such
as viral infection, alcoholic liver disease, and NASH, is a major global
health problem for which there is no effective treatment.1 As liver
fibrosis progresses, liver cirrhosis and liver cancer regularly demand
liver transplant.2 Hepatic stellate cells (HSCs) are essential in the pro-
gressionof liver fibrosis.HSCsareactivatedby inflammatory cytokines
and mediators to trans-differentiate into myofibroblasts, and become
themajor source of extracellular matrix including collagens in the liver
during the development of fibrosis.3,4
As an important component of the innate immune system, NK cells
respond rapidly to transformedor virus-infected cells, and kill such tar-
get cells without restriction by either major histocompatibility anti-
gen or a need for presensitization.5 NK cells have been implicated in
suppressing the pathogenesis of liver fibrosis,6 but the exact mecha-
nism remains elusive. It has been reported that NK cells selectively kill
early activated (transitional) or senescent-activated HSCs rather than
quiescent or fully activated HSCs (myofibroblasts).7 Activated HSCs
express less NK cell inhibitory ligand MHC-1,8 but strongly express
Abbreviations: HSC, hepatic stellate cell; poly I:C, polyinosinic–polycytidylic acid
ULBP-2 (UL16 binding protein 2), MICA/B (MHC class I polypeptide-
related sequence A/B),9 and RAE-1 (retinoic acid early inducible 1),7,10
which activate NK cells through engagement with NKG2D. This leads
to killing of activated HSCs by NKG2D-dependent degranulation of
NK cells.7,9 Additionally, NK cells induce HSCs apoptosis through FasL
with activated HSCs’ intense expression of Fas, as well as TRAIL-
mediated killing.7,9 NK cells also restrainHSCs activation through IFN-
𝛾 secretion.11 However, the effects of NK cells on HSCs through the
established mechanisms are attenuated as NK cells are deactivated
as liver fibrosis inexorably progresses, and impaired antifibrotic func-
tions of NK cells are associated with accelerated progression of liver
fibrosis.12 Therefore, the restoration and promotion of NK cell activity
might promote the regression of liver fibrosis.
IL-18 belongs to the IL-1 family. Once its 24 kDa precursor is
cleaved to the 18 kDa form by IL-1𝛽 converting enzyme (ICE, also
known as caspase-1), IL-18 acquires biologic function to promote
proliferation and cytolytic activity of NK and T cells combined with
IL-12 or IL-2.13,14 The immunostimulatory properties of polyinosinic–
polycytidylic acid (poly I:C), a surrogateTLR3 ligand, havebeenverified
in various pathologic circumstances in vivo.15 Furthermore, NK cell
activation in response to IL-18/IL-12 or IL-15/IL-12 stimulation is
enhanced by TLR3 agonists.16,17 However, the signaling pathway
by which IL-18 and poly I:C synergistically activate NK cells is not
clearly defined.
In the present study, we investigated the mechanisms by which NK
cells are activated by IL-18 and poly I:C to kill HSCs using human NK
cells from healthy donors and primary HSCs or LX2 cells. Our results
showed that IL-18 and poly I:C synergistically activate NK cells via the
p38/PI3K/Akt signaling pathway, and the activated NK cells kill HSC
in a TRAIL-involved degranulation manner. We thus propose that p38
MAP/PI3 kinasemight be a novel therapeutic target for intervention of
human liver fibrosis targeting NK cells.
2 MATERIALS AND METHODS
2.1 Human subjects
Buffy coats from healthy donors were provided by the Changchun
Blood Center, and informed consent was provided according to the
protocols of the Changchun Blood Center. Liver perfusion from
cadaver donors were collected as we described previously.18 All stud-
ies were conducted according to the experimental practices and stan-
dards that were approved by the Medical Ethics Committee of First
Hospital of Jilin University (approval code: 2015–125).
2.2 Cell isolation and purification
PBMCs were freshly isolated from peripheral blood of healthy indi-
viduals by Ficoll-Paque Plus (GE Healthcare, Uppsala, Sweden) den-
sity gradient separation. Liver mononuclear cells were freshly isolated
from liver perfusates as we described previously.18 For magnetic cell
sorting, NK cells were purified by NK cell isolation kit (Miltenyi Biotec,
Bergisch Gladbach, Germany). The purity of NK cells was approxi-
mately 95% as determined by flow cytometry (Supplemental Fig. S1A).
2.3 Cell culture
Purified NK cells were cultured in RPMI 1640 medium (Corning Life
Science, Lowell,MA,USA)with 10%FBSand1%Pen-Strep (GEHealth-
care). After stimulated with IL-18 (R&D System, Minneapolis, MN,
USA) or poly I:C (Sigma–Aldrich, Saint Louis, MO, USA) for 24 h in 24
wells plate, cells were collected for FACS analysis, the supernatants
were harvested for cytokine detection. To inhibit PI3K or p38 MAPK,
NK cells were pretreated in the presence of 50 𝜇MLY294002 (Sigma–
Aldrich) or 20 𝜇M SB202190 (Sigma–Aldrich) for 1 h and then stimu-
lated with IL-18 and/or poly I:C.
LX2 cells were cultured in DMEM medium (Corning Life Science)
supplemented with 10% FBS. Primary human HSCs purchased from
ScienCell (San Diego, CA, USA), and were cultured within 3 passages
in Stellate Cell Medium (ScienCell). The definition of LX2 cells and pri-
mary HSCswere shown as Supplemental Fig. S1B.
2.4 Cell coculture
NK cells stimulated with IL-18 and/or poly I:C were collected and
resuspended in fresh medium, and then cocultured with LX2 or pri-
mary HSCs, which were labeled with 1.25 𝜇MCFSE (Lifescience Tech-
nology, Carlsbad, CA, USA), in 24 wells plate at E:T = 1:1 for 5 h. For
transwell coculture experiments, NK cells were in the upper cham-
ber, whereas LX2 cells or primary HSCs were in the lower chamber
using the plates with 0.4 𝜇m pore diameter (Corning Life Science). For
the blocking experiments, IL-18/poly I:C-stimulatedNK cellswere pre-
treated with 50 𝜇M 3,4-DCI (Sigma–Aldrich) or 1 𝜇g/ml anti-TRAIL
(R&D System; Catalog number: AF375) for 1 h, and then cocultured
with LX2 or primary HSCs. For IFN-𝛾-blocking coculture experiments,
IL-18/poly I:C-primed NK cells were cocultured with LX2 or primary
HSCswith 1 𝜇g/ml anti-IFN-𝛾 supplied inmedium. Soluble TRAIL (R&D
System; Catalog number: 375-TL-010) was added to HSCs half hour
earlier than NK cells in coculture.
2.5 Flow cytometry
Cell staining and flow cytometry analysis were performed as
described.19 Briefly, the phenotypic and functional markers of
NK cell were characterized by staining with the following antibodies:
mouse anti-human NKp30-PE (BD Pharmingen; Catalog number:
558407; BD Biosciences, San Jose, CA, USA), mouse anti-human
NKp46-APC (BD Pharmingen; Catalog number: 558051), mouse
anti-human NKG2D-APC (BD Pharmingen; Catalog number: 558071),
mouse anti-human CD94-FITC (BD Pharmingen; Catalog number:
555888), mouse anti-human CD69-V450 (BD Horizon; Catalog num-
ber: 560740), mouse anti-human CD253-PE (BD Pharmingen; Catalog
number: 550516), mouse anti-human CD16-PE-Cy7 (BD Pharmin-
gen; Catalog number: 557744). Intracellular IFN-𝛾 was stained by
mouse anti-human IFN-𝛾-APC (BD Pharmingen; Catalog number:
551385). Phosphorylation of p38 MAPK or Akt were characterized
by staining with mouse anti-Akt-PE-CF594 (pS473; BD Phosflow;
Catalog number: 562465) or mouse anti-p38 MAPK-Pacific Blue
(pT180/pY182; BD Phosflow; Catalog number: 560313). For CD107a
detection, mouse anti-human CD107a-FITC (BD Pharmingen; Catalog
number: 555800) was added into medium for 5 h, and Golgi-Plug was
involved in the last 4 h, and cells were collected for flow cytometry.
For cell apoptosis analysis, LX2 and primary HSCs were stained with
Annexin V and PI using Apoptosis Detection Kit (BD Pharmingen;
Catalog number: 556547). Flow cytometry was performed using a BD
LSRFortessa flow cytometer (BDBiosciences). The data acquiredwere
analyzedwith FlowJo (Treestar software, Ashland, OR, USA).
2.6 ELISA
The cell culture supernatants were collected, and IFN-𝛾 concentra-
tions were measured by Human IFN-gamma ELISA Ready-Set-Go R©
(eBioscience, San Diego, CA, USA) according to the manufacturer’s
instructions.
2.7 NK cell siRNA transfection
Transfection were performed as described.20 Briefly, NK cells were
seeded in 24-well plates, and transfected with SignalSilence R© p38
MAPK siRNA I (Cell Signalling Technology, Danvers, MA, USA) or
AllStars Negative Control siRNA (QIAGEN, Germantown, MD, USA)
using HiPerFect Transfection Reagent (QIAGEN) before IL-18/poly
I:C stimulation.
F IGURE 1 IL-18 and poly I:C synergistically activate NK cells. Purified NK cells were treated with IL-18 or/and poly I:C at indicated concentra-
tion for 24 h. IFN-𝛾 expression wasmeasured by intracellular stain (A). IFN-𝛾 secretion in the supernatant was detected by ELISA (B). CD69/TRAIL
NKp46/NKp30/NKG2D/CD94 expression on NK cells was analyzed by flow cytometry (C). Results were shown as mean ± SEM of 6 independent
experiments performedwith 6 different donor samples. **P< 0.01 and ***P< 0.001, paired t-test
2.8 Western blot analysis
Purified NK cells stimulated with IL-18 and/or poly I:C were collected
and lysed for Western blotting analysis as described previously.21
Briefly, cells were collected by centrifugation and resuspended in
RIPA buffer (Cell Signalling Technology) to extract protein. Protein
extracts were resolved on a 10% SDS-PAGE under constant Volt-
age condition. After electrophoresis, protein was transferred to a
transfer membrane (Merck Millipore, Darmstadt, Germany). Blots
were incubated at room temperature for 1 h and at 4 ◦C overnight
with anti-p38 (Cell Signalling Technology; Catalog number: 9212),
anti-Akt (Cell Signalling Technology; Catalog number: 9272), anti-
MAPKAPK-2 (Cell Signalling Technology; Catalog number: 3042),
anti-phosphorylated p38 (Cell Signalling Technology; Catalog num-
ber: 4511), anti-phosphorylated Akt (Cell Signalling Technology; Cata-
log number: 4060), anti-phosphorylated MAPKAPK-2 (Cell Signalling
Technology; Catalog number: 3041), and anti-beta-actin (Cell Sig-
nalling Technology; Catalog number: 4970). After washed 3 times by
0.1% tween20 (Amresco, Solon,OH,USA)PBS, peroxidase-conjugated
anti-rabbit IgG (Proteintech, Rosemont, IL, USA; Catalog number:
10545-2-AP) was involved for another 1 h at room temperature.
Immunoreactivity was determined by using ECL kit (PerkinElmer,
Waltham, MA, USA) by XRS+ (BIO-RAD, Hercules, USA). Results were
analyzed by Image Lab (BIO-RAD).
2.9 Live cell imaging
Live cell imagingwas performed as described.22 LX2 cells were seeded
in glass bottom dish (In Vitro Scientific, Mountain View, CA, USA)
and cultured for 30 min. Then prestimulated NK cells as described
above were added at NK: HSC ratio of 2:1 and immediately coincu-
bated by using DeltaVision Elite (GE Healthcare, Buckinghamshire,
UK). Cells were maintained in a 37 ◦C, 5% CO2 chamber while videos
were recorded.
2.10 Statistical analysis
All datawere analyzed using theD’Agostino and Pearson omnibus nor-
mality test. P values of <0.05 were considered statistically significant.
Mean values were compared using either a paired t-test (2 groups) or
ANOVA (more than 2 groups), followed by a Bonferroni correction for
multiple comparisons test. All statistical tests were performed using
GraphPad Prism software (San Diego, CA, USA).
2.11 Online supplemental material
Supplemental Figs. S1–S3 and Supplemental Videos S1–S3 were
included as Online SupplementalMaterial.
3 RESULTS
3.1 IL-18 and poly I:C synergistically activate NK
cells to express IFN-𝜸, TRAIL, and CD69
To investigate whether IL-18 and poly I:C activate NK cells, we first
purified NK cells from peripheral blood of healthy donors, and the
distribution of CD56dimCD16+/ CD56brightCD16– subsets was shown
as Supplemental Fig. S2B. Then purified NK cells were stimulated
F IGURE 2 IL-18andpoly I:C synergistically activatep38MAPK/PI3K/Akt to induceNKcell activation.PurifiedNKcells (n=3)were stimulated
with IL-18 or/and poly I:C for 30 min, the expression of p38MAPK, Akt, STAT3, mTOR, and the phosphorylation of p38MAPK, Akt, STAT3, mTOR
was determined byWestern blot. 𝛽-Actin was used as loading control (A). NK cells were pretreated with PI3Ki (LY294002) or p38i (SB202190) for
1 h, and then stimulatedwith IL-18 and/or poly I:C, the expression and phosphorylation of Akt,MAPKAPK-2, p38MAPKwasmeasured byWestern
blot (n= 3, B) or flow cytometry (n= 3, C). NK cells were transfected with control siRNA or p38 siRNA before stimulated by IL-18 and poly I:C, the
expression of p38 MAPK, Akt, 𝛽-actin, and the phosphorylation of Akt were detected by Western blot (B). The expression of IFN-𝛾 in NK cells
(n = 6) was measured by intracellular cytokine staining (D) and ELISA (E). CD69 and TRAIL expression on NK cells (n = 6) were detected by using
flow cytometer analysis (F). Results are shown as mean ± SEM of the indicated numbers of independent experiments performed with different
donor samples. *P< 0.05, **P< 0.01, and ***P< 0.001, paired t-test; ns, not significant
with the optimal concentration of IL-18 (100 ng/ml) and/or poly I:C
(50 𝜇g/ml) as determined in Supplemental Fig. S2C. IFN-𝛾 production
was analyzed by intracellular staining and ELISA, the activating recep-
tor and inhibitory receptor expressed on NK cells were examined by
flow cytometry. Consistent with liver NK cells,23 IL-18 and poly I:C
synergistically induce IFN-𝛾 expression (P < 0.01; Fig. 1A) and produc-
tion (P< 0.01; Fig. 1B) as well as TRAIL expression (P< 0.01; Fig. 1C) of
peripheral NK cells, compared with IL-18 or poly I:C alone. Moreover,
we observed that IL-18 and poly I:C synergistically up-regulate CD69
expression (P< 0.01), but fail to affect Nkp30/ Nkp46/ NKG2D/ CD94
expression onNK cells (Fig. 1C).
3.2 IL-18 and poly I:C synergistically activate NK
cells via p38MAPK/PI3K signaling pathway
We further investigated the mechanism by which IL-18 and poly I:C
synergistically activate NK cells. Purified NK cells were stimulated
with IL-18 and/or poly I:C, the protein expression and phosphorylation
levels of Akt, p38, STAT3, and mTOR were determined by Western
blots. The results showed that the phosphorylation of p38 and Akt,
but not STAT3 and mTOR, are activated by the synergy of IL-18 and
poly I:C, whereas neither IL-18 nor poly I:C alone did (P< 0.05; Fig 2A).
To define the signaling pathway of IL-18/poly I:C-induced NK cell acti-
vation, the inhibitors of p38 (SB202190) and PI3K (LY294002) were
added toNK cells before stimulationwith IL-18 and poly I:C. The phos-
phorylation levels of Akt, p38, and MAPKAPK-2 (directly phosphory-
lated by p-p38) were examined by Western blot and flow cytometry,
IFN-𝛾 production by intracellular staining and ELISA, and the expres-
sion of CD69 and TRAIL by flow cytometry. We observed that either
SB202190 or LY294002 inhibit IL-18/poly I:C-induced Akt phospho-
rylation (P < 0.05), but LY294002 fail to inhibit IL-18/poly I:C-induced
activation of p38/MAPKAPK-2 (Figs. 2B and C). Phosphorylation
levels of Akt were reduced when NK cells were transfected with p38
siRNA (Fig. 2B), suggesting that PI3K/Akt is downstream signaling of
p38 in IL-18/poly I:C-activatedNKcells.Moreover, bothLY294002and
SB202190 inhibit IL-18/poly I:C-induced IFN-𝛾 expression (P < 0.01;
F IGURE 3 HSCs activate IL-18/poly I:C-primedNK cell degranulation.NK cells stimulatedwith IL-18 and/or poly I:C were collected and resus-
pended in fresh medium, and then cocultured with LX2, primary hepatic stellate or K562 cells at E: T = 1:1, the expression of CD16 and CD107a
was analyzed by flow cytometry (A). NK cells were pretreated with SB202190 or LY294002 before IL-18 and poly I:C stimulation, and then cocul-
tured with LX2 or primary HSCs, CD107a expression was shown (B). CD107a expression was shown when transwell-coculture was used to sep-
arate NK cells from LX2 or primary HSCs (C). Anti-IFN-𝛾 or isotype antibody were added in coculture, and CD107a expression of NK cells were
detected (D). Resultswere shownasmean± SEMof 6 independent experiments performedwith 6different donorNKcells. **P<0.01, ***P<0.001,
paired t-test
Fig. 2D) and production (P < 0.01; Fig. 2E) as well as TRAIL expression
(P < 0.001; Fig. 2F). The CD69 expression induced by IL-18/poly I:C,
however, is only inhibited by SB202190 (P < 0.001) but not LY294002
(Fig. 2F). It indicates that IL-18/poly I:C-activated p38/PI3K/AKT
signaling pathway is involved in IFN-𝛾 and TRAIL expression, and an
alternative p38 signaling pathway in CD69 expression onNK cells.
3.3 HSCs activate IL-18/poly I:C-primed
NK cell degranulation
During liver injury, the activation of HSCs in response to hepatocyte
damage results in the increased NK cell stimulation and decreased
NK cell inhibition.4 We further determined whether HSCs activate
IL-18/poly I:C-primed NK cell degranulation. IL-18 and/or poly I:C-
pretreated NK cells were cocultured with LX2 cells, primary HSCs, or
K562 cells. CD107a expression level of NK cells was used to evaluate
the primed NK cell degranulation using flow cytometer analysis. As
the results shown in Fig. 3A, IL-18/poly I:C-pretreated NK cells, which
were cocultured with HSCs or K562 cells, show significantly higher
CD107a expression than that of IL-18 or poly I:C alone pretreated
NK cells (P < 0.01), whereas both LX2 cells and primary HSCs induce
slightly CD107a expression of IL-18 or poly I:C pretreated NK cells,
but not rest NK cells. As control, IL-18 and/or poly I:C could not
directly induce the CD107a expression of NK cells without target cell
stimulus, K562 cells induce the CD107a expression of rest NK cell.We
also observed that CD107a expression is also suppressed when NK
cells were treated with inhibitors of PI3K or p38 before stimulated by
IL-18 and poly I:C (P< 0.01; Fig. 3B). CD107a expression is completely
blocked using transwell to separate IL-18/poly I:C-pretreated NK cells
from LX2 cells or primary HSCs (P< 0.001; Fig. 3C). But neutralization
of IFN-𝛾 in coculture did not affect CD107a expression (Fig. 3D). This
suggests that HSCs induce the degranulation of IL-18/poly I:C-primed
NK cells in a cell–cell contact-dependent manner, and that IL-18/poly
I:C-activated p38/PI3K/AKT signaling is required for HSC-inducedNK
cell degranulation.
3.4 IL-18/poly I:C-primedNK cells reciprocally
induce HSCs death through degranulation
Next, to investigate IL-18/poly I:C-primed NK cell cytotoxicity to
HSCs, CFSE-labeled LX2 cells or primary HSCs were cocultured with
IL-18 and/or poly I:C-primed NK cells. Cell gating strategy was shown
F IGURE 4 IL-18/poly I:C-primed NK cells reciprocally induce HSC death through degranulation. Primary HSCs or LX2 cells were cocultured
with IL-18- and/or poly I:C-pretreated NK cells, the cell death was evaluated by AnnexinV and PI staining. The cell death of primary HSCs and LX2
cellswas shown (A).NKcellswere pretreatedwithPI3Ki (LY294002) or p38i (SB202190) before IL-18 andpoly I:C stimulation, and then cocultured
with LX2 or primaryHSCs, the cell death of HSCswas shown (B). PrimaryHSC and LX2 cell deathswere shownwhen transwell-coculturewas used
to separate LX2or primaryHSCs fromNKcells (C). IL-18 andpoly I:C-stimulatedNKcellswerepretreatedwith3,4-DCI before coculturedwith LX2
or primary HSCs, and the cell death of LX2 and primary HSCs was shown (D). Results were shown as mean ± SEM of 6 independent experiments
performedwith 6 different donor NK cells. **P< 0.01, ***P< 0.001, paired t-test; ns, not significant
in Supplemental Fig. S2D, the cell death of LX2 and primary HSCs
were evaluated with PI+/AnnexinV+ . We observed that the activated
NK cell-induced HSC death is dependent on the NK cells/HSCs ratio
(Supplemental Fig. S2E), and E/T ratio = 1:1 was used in the follow-
ing NK cells/HSCs coculture experiments. IL-18/poly I:C-pretreated
NK cells significantly induce the cell death of primary HSCs and LX2,
compared with IL-18 or poly I:C alone pretreated NK cells (P < 0.01;
Fig. 4A), whereas pretreated NK cells with medium did not do that.
The cell death of primary HSCs and LX2 was suppressed by PI3K
or p38 inhibitors, which were added to NK cells before stimulated
with IL-18 and poly I:C (P < 0.01; Fig. 4B). Transwell, which was
used to separate primary HSCs or LX2 cells from IL-18/poly I:C-
activated NK cells in coculture, completely inhibits primary HSCs and
LX2 cell death (P < 0.01; Fig. 4C). Furthermore, when IL-18/poly I:C-
activated NK cells were pretreated with GranzymeB inhibitor (3,4-
dichloroisocoumarin) before cocultured with LX2 cells or primary
HSCs, the cell death of primary HSCs and LX2 is entirely inhibited as
well (P< 0.001; Fig. 4D). However, neutralization of IFN-𝛾 by anti-IFN-
𝛾 antibody in cell coculture did not affect the cell death of LX2 and
primary HSCs (Supplemental Fig. S3A). These data indicate that NK
cell cytotoxicity to HSCs occurs through degranulation in a cell–cell
contact-dependentmanner, but not directly through IFN-𝛾 production.
3.5 IL-18/poly I:C-primedNK cells kill HSCs in a
TRAIL-involved degranulationmanner
Previous studies reported that NK cells induce a rapid apoptosis of
HSCs through TRAIL7,9 or degranulation.8,20 We thus investigated the
role of TRAIL in NK cells killing HSCs. Primary HSCs and LX2 cells
expressed TRAIL-R2 and TRAIL-R4 (Supplemental Fig. S3B). Using
anti-TRAIL antibody or soluble TRAIL (sTRAIL) in HSC/NK cell cocul-
ture for theblockadesofTRAILorTRAIL receptor,whichareexpressed
on NK cells or HSCs, respectively, the expression levels of CD107a or
PI/AnnexinV were used to evaluate NK cell degranulation or HSC cell
death. We observed that the blockades of TRAIL and TRAIL recep-
tor with anti-TRAIL and sTRAIL inhibit the cell death of LX2 and pri-
mary HSCs (P < 0.01; Fig. 5A and B), as well as NK cell degranulation
(P< 0.05; Fig. 5C andD).
To further analyze the immune synapse of HSC/NK cell interaction,
we visualized LX2 cells and PKH26-labeled NK cells coculture by live
cell imaging for 150 min. As shown in Fig. 5E and Supplemental Video,
IL-18/poly I:C-activated NK cells rapidly induce LX2 cell budding after
adhesion (Supplemental Video S2) contrast to resting NK cells (Sup-
plemental Video S1). Consistently, the blockade of TRAIL inhibited
LX2 cell budding (Supplemental Video S3). Besides, PKH26-labeled
F IGURE 5 IL-18/poly I:C-primed NK cells kill hepatic stellate cells in a TRAIL- involved degranulation manner. IL-18 and poly I:C-primed NK
cells were treated by anti-TRAIL or isotype antibody before coculture. HSC death was measured (A), and NK cell degranulation was evaluated by
CD107a expression (C). Soluble TRAIL was added to cell coculture, the cell death of HSCs (B) and CD107a expression of NK cells (D) was shown.
Results were shown as mean ± SEM of 6 independent experiments performed with 6 different donor NK cells. *P < 0.05, **P < 0.01, ***P < 0.001,
paired t-test. The kinetics of the activated NK cell-mediated LX2 cell apoptosis were observed by using live-cell imaging (E)
NK cells were cocultured transiently with CFSE-labeled LX2 cells and
washed gently to removeunattachedNKcells. The results showed that
anti-TRAILdecrease thenumberof adhesiveNKcells onLX2cells (Sup-
plemental Fig. S3C).
Taken together, these data suggest that the engagement of TRAIL
expressed on activated NK cells with TRAIL receptors expressed on
HSCs play a role in the immune synapse formation, which initiates NK
cell degranulation to kill HSCs.
3.6 IL-18/poly I:C-primed hepatic NK cells kill HSCs
in a TRAIL-involved degranulationmanner
Finally, to testify whether IL-18 and poly I:C increase hepatic NK cell
cytotoxicity to HSCs as peripheral NK cells did, we isolated hepatic
NK cells from liver perfusate of cadaver donors to establish hepatic
NK cells and primary HSCs coculture as we did in peripheral NK cells.
As expected, primary HSCs activate IL-18/poly I:C-primed hepatic NK
cell degranulation (P< 0.05; Fig. 6A). IL-18/poly I:C-primed hepatic NK
cells induce the cell death of primary HSCs (P < 0.01; Fig. 6B). More-
over, blockade of TRAIL with anti-TRAIL antibody inhibit hepatic NK
cell degranulation (P<0.05; Fig. 6C) and the cell deathof primaryHSCs
(P< 0.01; Fig. 6D).
4 DISCUSSION
We have previously reported that poly I:C induces IL-18 expression
in Kupffer cells to activate liver NK cells.19 Liver NK cells are also
synergistically activated by IL-18 and poly I:C to produce IFN-𝛾
and express TRAIL on their surface.23 But the mechanism by which
IL-18 and poly I:C synergistically activate NK cells remains to be
defined. In the present study, our results showed that consistent
with hepatic NK cells, the synergy of IL-18 and poly I:C activate NK
cells (Fig. 1). We further found that IL-18 and poly I:C synergistically
induce NK cell activation through P38/PI3K/AKT signaling pathway
(Fig. 2). IL-18 signaling is MyD88 (Myeloid differentiation primary
response gene 88) dependent,13 whereas poly I:C/TLR3 signal-
ing is TIR-domain-containing adapter-inducing interferon-𝛽 (TRIF)
dependent and MyD88 independent.16 Downstream of TRIF and
MyD88, signaling as ERK,24 NF-𝜅B,25 IFN regulatory factor 5 (IRF5),26
F IGURE 6 IL-18/poly I:C-primed hepatic NK cells kill HSCs in a TRAIL-involved degranulationmanner. LiverNK cells were purified from speci-
men, then primed by IL-18 and/or poly I:C before coculturedwith primaryHSCs as above. CD107a expression of liver NK cells (A) and PI/AnnexinV
level of primary HSCs (B) were detected. Anti-TRAIL or isotype antibody were used to treat IL-18/poly I:C-primed liver NK cells before cocultured
with primary HSCs, then CD107a expression of liver NK cells (C) and the cell death of primary HSCs (D) was measured. Results were shown as
mean± SEMof 5 independent experiments performedwith 5 different donor NK cells. *P< 0.05, **P< 0.01, paired t-test
and p3827 could be the coordinates of these 2 pathways. IL-12 plus
IL-18 stimulate greater IFN-𝛾 secretion by resting NK cells through
stabilization of IFN-𝛾 mRNA via p38 MAPK,28 and highly augment
human NK cell cytotoxicity and degranulation in vitro.29 p38 MAPK
activation controls poly I:C-enhanced cytotoxicity and poly I:C/ IL-12-
costimulated IFN-𝛾 secretion in human NK cells.30 There is emerging
evidence about cross-talk between p38MAPK and PI3K/Akt signaling.
TLR2-mediated interplay between MAPK and PI3K signaling axis
controls ESAT-6 (early secreted antigenic target protein 6) induced
expression of cyclooxygenase-2 in macrophages.31 PI3K/Akt/eNOS
inhibit p38 MAPK and maintain the integrity of vasculature in mouse
lung.32 P38/PI3K/Akt signaling activates heat shock protein 27 to
antagonize melatonin-induced apoptosis of gastric cancer cells.33
The synergy between Poly I:C/TLR3/TRIF and IL-18/MyD88 sig-
naling pathways may be mediated via IRF5 to activate the NF-𝜅B
transcription factor through the canonical pathway,26 which we
identified it as p38/PI3K/Akt signaling pathway. To our knowledge, this
is the first description of NK cell activation via the p38 MAPK/PI3K
signaling pathway.
NKcells play an important role in inhibition of liver fibrosis by killing
HSCs.4,11 The present study provided several lines of evidence to sup-
port a novel mechanism by which IL-18/poly I:C activated NK cells via
p38/PI3K/AKT signaling kill HSCs. First, HSCs activate IL-18/poly I:C-
pretreated NK cell degranulation (Fig. 3), and IL-18/poly I:C-activated
NK cells reciprocally induce HSCs death through degranulation
(Fig. 4). The interaction between NK cell and HSCs is dependent on
cell-cell contact and IL-18/poly I:C-activated p38/PI3K/AKT signaling
in NK cells, but independent on IFN-𝛾 production. The direct cytotoxic
degranulation of NK cells killing HSCs depends on the engagement
between NKG2D of NK cells with ULBP-2, MICA/B, and RAE-1 of
HSCs and NK activation via p38/PI3K/AKT signaling pathway to
release perforin and Granzyme.4,8,11,20 Although IFN-𝛾 enhances NK
cells TRAIL expression23 and cytotoxicity to HSCs,7,34 it has no direct
cytotoxic effect against HSCs in 5 h coculture (Supplemental Fig. S3A).
It has been demonstrated that activated NK cells killing HSC
occurred 2 separate pathways: direct cytotoxic degranulation of NK
cells4,8,11,20 and TRAIL-induced apoptosis.7,9 However, the present
study showed that blockades of engagement between TRAIL with
TRAIL receptor inhibit NK cell-induced HSC apoptosis as well as
NK cell degranulation (Figs. 5A–D). Using the live-cell image we
found that IL-18/poly I:C-activated NK cells rapidly induce LX2 cells
death, and the blockade of TRAIL obviously inhibit the interaction
between NK cells and LX2 cells (Fig. 5E). NK cells’ natural cytotoxicity
is activated by interactions between different ligand–receptor pairs,
and requires composed signals of adhesion, granule polarization and
degranulation.35 As a prerequisite for NK cell effector functions, the
engagement of TRAIL and TRAIL receptor is suggested supplying
the basis for the formation of an immune synapse by rendering a
firm connection with HSCs (Supplemental Fig. S3C). Previous study
indicated that ligation of membrane TRAIL and its receptors trans-
duced a costimulation signal and acted as a coreceptor of TCR in
T cells.36 Ligation of the TRAIL by its soluble receptor, DR4-Fc, alone
induced phosphorylation of Lck and ZAP70, resulting in activation of
the downstream NF-kB pathway. Integration of the TRAIL with TCR
signaling is via enhanced lipid raft recruitment of Lck, which integrates
mitogenic NF-kB-dependent signals from the TCR and TRAIL in
T lymphocytes.37 In activated NK cells, membrane TRAIL supplements
the perforin/granzyme cytotoxic pathway, contributing to TRAIL-
resistant neuroblastoma cell lysis.38 These findings suggest that in
addition to directly induce HSC apoptosis, NK cell membrane TRAIL
binding to its receptors is involved in NK cell cytotoxic degranulation
to HSCs. But themechanism needs to be further investigated.
On the basis of CD56 and CD16 expression, human NK cells can
be divided into 2 functional subsets of cytokine secretion and cyto-
toxic effector. Overall, approximately 90%of peripheral bloodNK cells
are CD56dim CD16+ cells, which efficiently kill target cells with low
secretion of cytokines. In contrast, CD56bright CD16– NK cells, which
produce large amounts of cytokines with low cytolytic activity, com-
pose of <10% peripheral blood NK cells, but represent up to 70% of
total NK cells in the liver.39 NK cells traffic between liver and periph-
eral blood,39,40 also redistribute in liver and spleenduringTLR3-ligand-
induced inflammation of liver.41 NK cells arewidely distributed in both
lymphoid (bone marrow and liver) and non-lymphoid organs (periph-
eral blood, lung, and uterus), and peripheral NK cells could accumulate
into liver and attenuate hepatic fibrosis.41,42 Although themain subset
of human blood NK cells is represented by NK56dim cells that are phe-
notypically and functionally different from liver resident NK cells that
are mainly represented by NK56bright subset, hepatic NK cells are also
synergistically activated by IL-18 and poly I:C to produce IFN-𝛾 and
express TRAIL on their surface.23 In this study, we showed the signal-
ing pathway through which this occurs, and reproduced that IL-18 and
poly I:C synergistically induce the degranulation in hepatic NK cells to
kill HSCs in TRAIL-involved manner as peripheral NK cells did (Fig. 6).
It makesmore relevant in pathophysiologic context of liver fibrosis.
NK cells play a paradoxical role in the development of liver fibrosis.
On one hand, NK cells can enhance liver injury by killing stressed hep-
atocytes via engagement of NKG2D, NKp30, and/or TRAIL, leading to
the development of fibrosis.43 On other hand, the cytotoxic activity of
NK cells plays an important role in inducing HSC apoptosis and thus
curtailing the progression of fibrosis.7 However, NK cells are deacti-
vated in chronic liver injury of some etiologies such as viral infection,
and incapable of killing the activated HSCs.12 The better understand-
ing of the contributions of NK cells to liver fibrosis will benefit for
developing therapeutics that target the restoration and promotion of
NK cells. Targeting of p38MAP/PI3 kinase inNK cell activitymay be as
an intervention strategy against liver fibrosis in the clinic setting.
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